Back to Agenda
Session 1: Digital Labeling and Panel Discussion Continued
Session Chair(s)
Rie Matsui, RPh
Senior Director, Regional Labeling Head for APAC, International Labeling
Pfizer R&D Japan G.K., Japan
Deborah Bebbington
Head Global Labeling
Bayer Plc, United Kingdom
There are many on-going initiatives of digital labeling across regions such as European Union, Japan, Canada and Singapore, although paper labeling is still required in majority of countries. eLabeling will help to deliver the latest labeling information immediately in efficient and customer friendly way for patients safety. Also, eLabeling is driven by the acceleration of digital disruption and must consider patient-centricity. In this session, the current landscape of eLabeling initiatives for future digital health across regions will be shared and will be discussed from regulators’ and industry’s point of view.
Learning Objective :
At the conclusion of this session, participants should be able to:
- Understand the updates on eLabeling landscape across regions
- Learn the company initiative on digital labeling
- Discuss digital labeling for future digital health
- Discuss the impact of eLabeling on company labeling process
Speaker(s)
Update on Health Canada's XML Product Monograph Project
Craig Anderson
Pfizer Inc , Canada
Director, International Labeling
European Product Information – ePI Hot Air or Real Opportunities?
Aimad Torqui
Medicines Evaluation Board, Netherlands
Division Head Medicines Evaluation Board
The Electronic Patient Leaflet Project (e-PIL) : A Pioneer Pilot in Belgium and Luxembourg
Nathalie Lambot, DrSc, MPharm, RPh
pharma.be , Belgium
Expert Santé Publique – Clinical Trials & Regulatory Affairs
Electronic Labeling: A U.S. Perspective
Mark Hendrickson, MS
Leavitt Partners, United States
Senior Director
Asia Updates for E-Labeling
Rie Matsui, RPh
Pfizer R&D Japan G.K., Japan
Senior Director, Regional Labeling Head for APAC, International Labeling
Have an account?